Reach Us +44-1904-929220
Current Status of Biomarker Discovery in Human clear Cell Renal Cell Carcinoma | OMICS International | Abstract

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Current Status of Biomarker Discovery in Human clear Cell Renal Cell Carcinoma

Simon J. Cooper1*, Han W. Tun2, Stephen M. Roper3, Yunee Kim4, Thomas Kislinger4, Richard R. Drake3 and John A. Copland1

1Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center

2Division of Hematology/Oncology, Internal Medicine Department, 4500 San Pablo Road, Mayo Clinic, Jacksonville, Florida, 32224, USA

3MUSC Proteomics Center and the Department of Molecular and Cellular Pharmacology and Experimental Therapeutics, Medical University of South Carolina,
Charleston, SC, 29425, USA

4Department of Medical Biophysics and Ontario Cancer Institute, University of Toronto, Ontario M5G 1L7, Canada

*Corresponding Author:
Simon J. Cooper
Department of Cancer Biology
Mayo Clinic Comprehensive Cancer Center
4500 San Pablo Road, Jacksonville, Florida, 32224, USA
Tel: +904-953-6045
Fax: +904-953-0277
E-mail: [email protected]

Received date: September 20, 2011; Accepted date: December 15, 2011; Published date: January 05, 2012

Citation: Cooper SJ, Tun HW, Roper SM, Kim Y, Kislinger T, et al. (2012) Current Status of Biomarker Discovery in Human clear Cell Renal Cell Carcinoma. J Mol Biomark Diagn S2:005. doi:10.4172/2155-9929.S2-005

Copyright: © 2012 Cooper SJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


The incidence of clear cell renal cell carcinoma (ccRCC) continues to increase while very few treatment options are available for therapy. Development of metastatic disease dramatically decreases patient survival; therefore detection at an early stage while still localized to the renal capsule is imperative for a favorable prognosis. With recent advances in molecular technologies and subsequent understanding of the underlying pathology of disease, molecular markers have been defined that are predicative of tumor stage, metastatic potential and patient prognosis. Analysis of these biomarkers along with current staging techniques already used in the clinic may allow for implementation of personalized post-surgical treatment plans as well provide further molecular pathways for targeted therapeutic interventions. In this review we will highlight the potential ccRCC biomarkers that have been identified through a variety of molecular techniques to date, and provide insight into research models for biomarker discovery.

Recommended Conferences

15th Global Biomarkers and Clinical Research Summit

Vienna, Austria

2nd International Conference on Biomarkers and Cancer Targets

Capetown, South Africa
Share This Page